Vps10p-domain receptor modulation for synaptic plasticity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mental and behavioral disorders primarily alleviate symptoms rather than addressing the underlying causes, and there is a need for therapies that target the signaling pathways regulating synaptic plasticity.
Innovation Solution
Modulation of Vps10p-domain receptors, specifically through agents that interact with Sortilin, SorCS2, SorCS1, and SorCS3, to regulate synaptic plasticity and neuronal activity, which can be achieved by enhancing or inhibiting the activity of these receptors or their interactions with binding partners like p75NTR, TrkB, and BDNF.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for mental and behavioral disorders are used, then symptoms are alleviated, but the underlying causes are not addressed
Solution Approach 1:
The patent extracts and targets specific signaling pathways (Vps10p-domain receptors, p75NTR, TrkB, BDNF) that are fundamentally involved in synaptic plasticity and neuronal activity. By isolating these specific molecular targets, the treatment addresses the root cause rather than just symptoms, while maintaining manageable complexity through focused pathway modulation
Solution Approach 2:
The patent employs agents that preemptively modulate receptor activity to prevent or correct aberrant signaling pathways before they fully manifest as symptomatic behavior. By intervening at the molecular level in synaptic plasticity pathways, the treatment addresses underlying causes proactively rather than reactively treating symptoms
2Reliability
If Vps10p-domain receptors are modulated to regulate synaptic plasticity, then underlying causes of disorders are addressed, but treatment complexity increases
Solution Approach 1:
The patent utilizes Vps10p-domain receptors that serve multiple functions in neuronal signaling, synaptic plasticity, and neurotrophin regulation. By targeting this multi-functional receptor family, a single treatment mechanism can address multiple aspects of synaptic dysfunction underlying various mental and behavioral disorders, reducing overall treatment complexity while maintaining high effectiveness
Solution Approach 2:
The patent employs small molecule agents or peptides as intermediaries that bind to Vps10p-domain receptors to modulate their activity. These intermediary molecules translate the therapeutic intent into specific molecular interactions, enabling controlled modulation of complex signaling pathways involving p75NTR, TrkB, and BDNF without requiring direct manipulation of the entire signaling network
Data Source
AI summary
The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of mental and behavioral disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention further-more relates to methods of altering expression of said receptors in vivo.